ADVERTISEMENT
Place of CEA in the evaluation of the treatment of metastatic colon cancer
There is a correlation between the rate of CEA and the tumor mass, rising rates are related to the degree of lymph local extension and the presence of distant metastases. In metastatic colorectal cancer, a constant elevation in the concentration of CEA may be associated with bad response to treatment or may persist lymph nodes remainders or subclinical metastases. A decrease in the concentration of ACE is usually indicative of a favorable prognosis and good response to treatment.
this is a retrospective study of metastatic colorectal cancer patients followed from 2020 to 2022, all patients made a determination of serum CEA at the diagnosis of metastasis and a second determination in the clinical and radiological assessment after treatment by chemotherapy; the dosing was also done in consultation control for patient with complete and partial response. The primary aim of this study is to evaluate the benefit of CEA assay in evaluating the efficacy of treatment and the secondary aim is benefit in monitoring of these patients after treatment.
99 patients were treated in the department, 66 patients had synchronous metastases and 33 patients had metachronous metastases. At diagnosis, in 19 cases the rate of CEA was normal and in 80 cases the rate was high. After treatment and radiological and clinical evaluation, evaluation of ACE found rate: 16 cases of normalization with complete response, 52 cases of rating decrease with partial response and 12 cases of elevated rates with radiological progression. Patient follow-up control, rising CEA levels occurs with recurrence of the disease for all patients.
In metastatic colorectal cancer, CEA assay is important to follow patients on treatment as it is high in the diagnosis; it helps to evaluate the effectiveness of treatment and monitoring of patients in the control consultation.
The authors.
Has not received any funding.
N. Caid: Disclosures not submitted; S. Bekouaci: Disclosures not submitted; H. Bouaaza: Disclosures not submitted. All other authors have declared no conflicts of interest.
